Moderna (MRNA) Stock Explodes 177% After Phase III Melanoma Vaccine Trial Success
TLDR
- Moderna stock jumped 177% on Wednesday after positive Phase III trial results for its melanoma cancer vaccine, intismeran.
- The move makes it only the second S&P 500 stock to more than double in a single day in 25 years.
- MRNA is now up 491% year-to-date, second only to Sandisk among S&P 500 performers.
- Analysts raised price targets and upgraded coverage but cautioned the good news may already be priced in.
- The stock pulled back after the initial surge as investors weighed valuation concerns.
Moderna stock hit 177% on Wednesday following Phase III trial results for intismeran, its personalized melanoma vaccine developed alongside Merck’s Keytruda. The stock opened at a jaw-dropping gain before pulling back as investors began digesting what the move actually means.
The rally pushed MRNA’s year-to-date gain to 491%, making it the second-best performing S&P 500 stock in 2026. Only memory-storage company Sandisk has done better. Dell, Micron, and Seagate round out the top five.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
